COPD Shingles Patient Prevention Study (ShiPPS)

Study under development; patient recruitment expected 3Q2020.
Health care professional recruiting may be delayed due to COVID-19.

Funded by: GSK as an Investigator-Sponsored Study

COPD Foundation Principal Investigator: Barbara Yawn, MD

Patient Investigator: Debbie Daro

Why ShiPPS?

Several studies have shown that individuals with COPD are at an increased risk of having acute shingles (also called herpes zoster [HZ]) as compared to individuals at the same age who do not have COPD. (Reference: Marra F, Panhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. doi:10.1093/ofid/ofaa005.)

  • Shingles is a condition caused by the virus that causes chickenpox. After healing from chickenpox, the virus, called Varicella-Zoster or Herpes-Zoster, stays in the body hibernating, and can be awakened or reactivated in later life to cause shingles. Shingles is a painful blistering rash that can occur anywhere on the body (usually in a "band" on one side). The rash can last from 1-4 weeks, but the pain and other complications may last for a very long time. People who have had one episode of shingles can have another one in the future. The infection is often treated with antiviral and pain medications, but their efficacy is limited. Shingles prevention through vaccination is possible and appears to be the best strategy.
  • Although two HZ vaccines have been approved by the US Food and Drug Administration (FDA), the US Centers for Disease Control (CDC) recommends that all healthy adults 50 years and older get two doses of the newer recombinant HZ vaccine (doses separated by 2 to 6 months), to prevent shingles and the complications from the disease.
  • More information on shingles and the vaccine is available at: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html

To date there is limited information on HZ vaccine use by people with COPD as well as in-office HZ vaccination and HZ vaccination recommendations from the health care professionals they see for COPD management. Information Is especially limited for vaccine recommendations and practices of pulmonologists, nurse practitioners and physician assistants.

About the study

ShiPPS is designed to help fill the information gap and to explore the impact of including a short HZ informational video embedded in a survey on the vaccine intentions of patients with COPD and the health care professionals providing their care. The study will also collect information on other older-adult vaccines that have had long-standing recommendations for individuals with COPD, specifically influenza (flu) and pneumococcal (pneumonia) vaccines.

This is a one-time survey study conducted in two groups of respondents:

  1. People with COPD enrolled in the COPD Foundation's COPD Patient Powered Research Network (PPRN)
  2. Clinicians who care for people with COPD in primary care and specialty settings

Partner Organizations

The COPD Foundation is partnering with the following organizations to support the administration of ShiPPS surveys:

  • American Academy of Family Physicians
  • American Association of Nurse Practitioners
  • American Academy of Physician Assistants
  • American Thoracic Society
  • American College of Chest Physicians

Interested in learning more?

Contact: ShiPPS e-mail: shipps@copdfoundation.org